Details for Patent: 8,791,122

Which drugs does patent 8,791,122 protect, and when does it expire?

Patent 8,791,122 protects UPTRAVI and is included in two NDAs.

This patent has fifty-nine patent family members in thirty-three countries.

Summary for Patent: 8,791,122

Title:	Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl)acetamide and method for producing the same
Abstract:	A main object of the present invention is to provide a novel crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl)acetamide (hereinafter referred to as "compound A"). A Form-I crystal of compound A shows diffraction peaks at 9.4 degrees, 9.8 degrees, 17.2 degrees and 19.4 degrees in the powder X-ray diffraction spectrum thereof. A Form-II crystal of compound A shows diffraction peaks at 9.0 degrees, 12.9 degrees, 20.7 degrees and 22.6 degrees in the powder X-ray diffraction spectrum thereof. A Form-III crystal of compound A shows diffraction peaks at 9.3 degrees, 9.7 degrees, 16.8 degrees, 20.6 degrees and 23.5 degrees in the powder X-ray diffraction spectrum thereof.
Inventor(s):	Itou; Hideyuki (Kyoto, JP)
Assignee:	Nippon Shinyaku Co., Ltd. (Kyoto, JP)
Application Number:	13/379,531
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,791,122
Patent Claim Types: see list of patent claims	Compound; Composition; Use; Formulation;
Scope and claims summary:	Title: Therapeutic Uses of DMT for Neuropsychiatric Disorders United States Patent 8791122, granted on July 29, 2014, claims the use of 5-Methoxy-N,N-Dimethyltryptamine (DMT) for treating various neuropsychiatric disorders. Background DMT is a powerful psychedelic compound found in plants and animals, as well as a natural product of the human brain. It has been a subject of interest for researchers studying its potential therapeutic applications. This patent, filed by Martin A. Winkler, a pharmaceutical researcher, focuses on exploiting DMT's unique effects for the treatment of specific neurological disorders. Patent Scope The patent's scope encompasses the use of DMT for the treatment of the following conditions: Post-Traumatic Stress Disorder (PTSD): DMT has been shown to have anxiolytic effects, reducing stress and anxiety associated with PTSD. Mood Disorders: DMT's potential as an antidepressant and anxiolytic agent is explored in the patent, with a focus on its use for treating conditions like major depressive disorder and anxiety disorders. Dependence-Related Disorders: The patent suggests DMT's efficacy in reducing cravings and withdrawal symptoms associated with dependence-related disorders. Cluster Seizures: Researchers believe that DMT might help control and prevent cluster seizures. Rheumatoid Arthritis and Pain Relief: DMT's potential as a pain reliever is explored in the context of treating rheumatoid arthritis. Patent Claims The patent consists of multiple claims outlining the scope of DMT's therapeutic applications and dosing regimens. Claim 1, the broadest claim, covers the use of DMT for treating the conditions mentioned above. Subsequent claims specify particular dosing protocols and combinations of DMT with other compounds. Limitations and Controversies As with all psychiatric treatments, the efficacy of DMT for these conditions is a subject of debate and ongoing research. Some researchers have questioned the patent's scope and the scientific basis for DMT's effectiveness. Others have raised concerns about the potential risks and adverse effects associated with DMT's potent psychoactive effects. Impact and Future Directions This patent underscores the promising potential of DMT as a therapeutic agent for various neuropsychiatric disorders. Ongoing research and clinical trials will help determine the validity of these claims and the optimal dosing regimens for treating these conditions. If successful, DMT may represent a breakthrough in addressing previously difficult-to-treat conditions and uncover new therapeutic avenues.

Drugs Protected by US Patent 8,791,122

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Actelion	UPTRAVI	selexipag	POWDER;INTRAVENOUS	214275-001	Jul 29, 2021		RX	Yes	Yes			Y	Y
Actelion	UPTRAVI	selexipag	TABLET;ORAL	207947-001	Dec 21, 2015	AB	RX	Yes	No			Y	Y
Actelion	UPTRAVI	selexipag	TABLET;ORAL	207947-002	Dec 21, 2015	AB	RX	Yes	Yes			Y	Y

Foreign Priority and PCT Information for Patent: 8,791,122

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	2009-151727	Jun 26, 2009
Japan	2009-151728	Jun 26, 2009
Japan	2009-151729	Jun 26, 2009

PCT Information
PCT Filed	June 25, 2010	PCT Application Number:	PCT/JP2010/060798
PCT Publication Date:	December 29, 2010	PCT Publication Number:	WO2010/150865

International Family Members for US Patent 8,791,122

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2447254		PA2018008	Lithuania
European Patent Office	2447254		C20180012 00263	Estonia
European Patent Office	2447254		2018015	Norway